Effect of a novel coronavirus in human and its clinical diagnosis and implications by students of community pharmacy

Kanamala Arun Chand Roby, Singamala Lakshmi Bhargavi, Gali Devi Sri, Avula Madhuri, Sannadi Kamakshi, Kurapati Bhagyaraj, Kudipudi Harinadha Baba


Coronavirus are coming under a broad family of virus that can cause respiratory illnesses such as the common cold, according to the centers for disease control and prevention (CDC). They are usual in many different species of animals, including camels and bats. Unusually, these corona viruses can evolve and infect humans and then spread between humans. Recent examples of this include SARS-CoV and MERS-CoV. 2019 Novel Corona virus (2019-nCoV) is a virus identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China. In some cases, the viruses can cause lower-respiratory tract illnesses such as pneumonia and bronchitis. In human corona viruses are currently classified into seven types that are HCoV-229E, HCoV-OC43, HCoV-NL63, SARS-CoV, HKU1, MERS-CoV and 2019-nCoV. These two types of corona virus (MERS-CoV and SARS-CoV) are more dangerous. Some of corona viruses like HCoV-229E, HCo-OC43, HCoNL63 and HKU1 that are continuously circulate in the population of human and cause respiratory infections in human either may children and adults world-wide. They are generally transmitted between animals and humans through sneezing, coughing, touching or shaking hands and making contact with a surface or object. The symptoms of corona virus are sneezing, cough, fatigue, runny nose, sore throat, breathing difficulty and exacerbated. In more severe cases SARS, kidney failure, pneumonia and even death. Diagnosis can be carried out by healthcare provider in laboratory test on respiratory specimens and serum to detect human corona virus. For this virus no specific treatment like vaccines and antiviral drugs but symptoms can be treated.


Coronavirus, Repurposing, Coagulopathy, Nasopharyngeal

Full Text:



WHO Statement Regarding Cluster of Pneumonia Cases in Wuhan, China? Retrieved; 2020.

Coronavirus Disease available at Doucleef M. Scientists Go Deep on Genes of SARS-Like Virus. Associated Press. Retrieved; 2012.

Coronavirus disease available at Falco M. New SARS-like virus poses medical mystery. CNN Health. Retrieved; 2013.

New SARS like virus found in Middle East. Al-Jazeera. Retrieved; 2013. Available at https://www.

Corona virus. Available at https//www.medicalnews Accessed on 24 January 2020

Corona virus. Available at: Accessed on 24 January 2020

Coronavirus outbreak. Available at: Accessed on 24 January 2020

Emergencies of novel coronavirus. Available at: Accessed on 02 February 2020

Lung cancer and corona virus. Available at: Accessed on 20 January 2020

Coronaviruses: An Overview of Their Replication and Pathogenesis. Available at: Accessed on 15 January 2020

Coronavirus (COVID-19). Available at: Accessed on 10 January 2020

Coronavirus (COVID-19). Available at: Accessed on 24 January 2020

International Committee on Taxonomy of Viruses (ICTV) October 2018. Archived from the original on 14 May 2019. Accessed on 24 January 2020.

ICTV Taxonomy history: ortho corona virinae. International Committee on Taxonomy of Viruses (ICTV). Accessed 24 January 2020.

Fan Yi, Zhao, Kai, Shi, Li Z, Zhou, Peng. Bat Coronaviruses in China. Viruses. 2019;11(3):210.

Groot DRJ, Baker SC, Baric R, Enjuanes L, Gorbalenya AE, Holmes KV, et al. Family Corona viridae. In AMQ King, E Lefkowitz, MJ Adams, EB Carstens (eds.). Ninth Report of the International Committee on Taxonomy of Viruses. Elsevier, Oxford; 2011: 806-828.

Li F, Li W, Farzan M, Harrison SC. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science. 2005;309(5742):1864-8.

Sexton NR, Smith EC, Blanc H, Vignuzzi M, Peersen OB, Denison MR. Homology-Based Identification of a Mutation in the Coronavirus RNA-Dependent RNA Polymerase That Confers Resistance to Multiple Mutagens. J Virology. 2016;90(16):7415-28.

Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Coronaviruses Methods Molecular Biology. 2015;1282:1-23.

Wu C. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B., In press, Available online 27 February 2020.

Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020;6:14.

Novac N. Challenges and opportunities of drug repositioning. Trends Pharmacol Sci. 2013;34(5):267-72.

Clercq DE, Li G. Approved antiviral drugs over the past 50 years. Clin Microbiol Rev. 2016;29(3):695-747.

Marston HD, Folkers GK, Morens DM, Fauci AS. Emerging viral diseases: confronting threats with new technologies. Sci Transl Med. 2014;6(253):253-10.

Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020;6:5883.

Qifang B, Yongsheng W, Shujiang M, Chenfei Y, Xuan Z, Zhen Z, et al. Epidemiology and transmission of COVID-19 in Shenzhen China: analysis of 391 cases and 1286 of their close contacts. Med Rxiv. 2020.

Mitja O. Bonaventura Clotet, use of antiviral drugs to reduce COVID-19 transmission. Lancet Glob Health. 2020.

Welliver R, Monto AS, Carewicz O, Schatteman E, Hassman M, Hedrick J, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA. 2001;285:748-54.

Xueting Y, Fei Y, Zhang M, Cheng C, Baoying Huang B, Peihua N, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020:237.

Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP et al. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutic, and therapeutics. Hum Vaccin Immunother. 2020:1-7.

Tocilizumab. 7 June 2019. Available at Accessed on 17 February 2020.

Slater H. FDA approves Phase III clinical trial of tocilizumab for COVID-19 pneumonia. Cancer Network, MJH Life Sci., 26 March 2020. Available at: Accessed on 17 February 2020.